1. Al-Malky, H.S., Al Harthi, S. E. and A.-M. M. Osman, (2020). Major obstacles to doxorubicin therapy: Cardiotoxicity and drug resistance, Journal of Oncology Pharmacy Practice, 26(2), 434-444. http://doi.org/10.1177/1078155219877931 [DOI:10.1177/1078155219877931] [PMID]

2. Bray, F., Laversanne, M., Weiderpass, E. and Soerjomataram, I. (2021). The ever‐increasing importance of cancer as a leading cause of premature death worldwide, Cancer, 127(16), 3029-3030. [DOI:10.1002/cncr.33587] [PMID]

3. Chen, Y., Shi, S. and Dai, Y. (2022). Research progress of therapeutic drugs for doxorubicin-induced cardiomyopathy, Biomedicine & Pharmacotherapy, 156, 113903. http://doi.org/10.1016/j.biopha.2022.113903 [DOI:10.1016/j.biopha.2022.113903] [PMID]

4. Gao, Z.G., Tian, L., Hu, J., Park, I.S. and Bae, Y.H. (2011). Prevention of metastasis in a 4T1 murine breast cancer model by doxorubicin carried by folate conjugated pH sensitive polymeric micelles, Journal of controlled release, 152(1), 84-89. http://doi.org/10.1016/j.jconrel.2011.01.021 [DOI:10.1016/j.jconrel.2011.01.021] [PMID] [PMCID]

5. Giaquinto, A.N., Sung, H., Miller, K.D., Kramer, J.L., Newman, L. A., Minihan A., et al., (2022) Breast cancer statistics, 72(6), 524-541. http:// doi.org/10.3322/caac.21754 [DOI:10.3322/caac.21754] [PMID]

6. Grady, W.M. (2021). Epigenetic alterations in the gastrointestinal tract: current and emerging use for biomarkers of cancer, Advances in cancer research, 151, 425-468. http://doi.org/10.1016/bs.acr.2021.02.006 [DOI:10.1016/bs.acr.2021.02.006] [PMID]

7. Khodakarami, A., Darvishi, S., Hassannia, H., Sadeghi, M., Esmaeeli, S., Hashemi V. et al., (2023). Blockade of CD155 and interleukin-6 suppresses breast cancer cell growth, International Journal of Drug Research in Clinics. 1, 2. http://doi.org/10.34172/ijdrc.2023.e10 [DOI:10.34172/ijdrc.2023.e10]

8. Mao H, Gu H, Qu X, Sun J, Song B, Gao W, et al, 2013. "Involvement of the mitochondrial pathway and Bim/Bcl-2 balance in dihydroartemisinin-induced apoptosis in human breast cancer in vitro. http://doi.org/10.3892/ijmm.2012.1176 [DOI:10.3892/ijmm.2012.1176] [PMID]

9. Masjedi, A., Ahmadi, A., Atyabi, F., Farhadi, S., Irandoust, M., Khazaei-Poul Y. et al, (2020). Silencing of IL-6 and STAT3 by siRNA loaded hyaluronate-N, N, N-trimethyl chitosan nanoparticles potently reduces cancer cell progression, International journal of biological macromolecules, 149, 487-500http://doi.org/10.1016/j.ijbiomac.2020.01.273 [DOI:10.1016/j.ijbiomac.2020.01.273] [PMID]

10. Masjedi, A., Hashemi, V., Hojjat-Farsangi, M., Ghalamfarsa, G., Azizi, G., Yousefi M. et al, (2018). The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer, Biomedicine & Pharmacotherapy, 108, 1415-1424. http://doi.org/10.1016/j.biopha.2018.09.177 [DOI:10.1016/j.biopha.2018.09.177] [PMID]

11. Mayrovitz, H. N. (2022). Breast Cancer. http://doi.org/10.1002/cncr.33587 [DOI:10.1002/cncr.33587] [PMID]

12. Park, M., Kim, D., Ko, S., Kim, A., Mo, K. and Yoon H., (2022). Breast cancer metastasis: Mechanisms and therapeutic implications, International Journal of Molecular Sciences, 23(12), 6806. http://doi.org/10.3390/ijms23126806 [DOI:10.3390/ijms23126806] [PMID] [PMCID]

13. Pulaski B.A. and Ostrand‐Rosenberg, S. (2000). Mouse 4T1 breast tumor model," Current protocols in immunology, 39(1), 1-16. [DOI:10.1002/0471142735.im2002s39] [PMID]

14. Qiu, H., Cao S., and Xu, R. (2020). Cancer incidence, mortality, and burden in China: a time‐trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020. 41(10), 1037-1048. http://doi.org/ 10.1002/cac2.12197 [DOI:10.1002/cac2.12197] [PMID] [PMCID]

15. Rivankar, S. (2014). An overview of doxorubicin formulations in cancer therapy, Journal of cancer research and therapeutics, 10(4), 853-858. http://doi.org/ 10.4103/0973-1482.139267 [DOI:10.4103/0973-1482.139267] [PMID]

16. Salimifard, S., Karoon Kiani, F., Sadat Eshaghi, F., Izadi S., Shahdadnejad, K., Masjedi A. et al., (2020). Retraction notice to Codelivery of BV6 and anti-IL6 siRNA by hyaluronate-conjugated PEG-chitosan-lactate nanoparticles inhibits tumor progression. Life Sciences, 260, 118423. http://doi.org/10.1016/j.lfs.2024.122774 [DOI:10.1016/j.lfs.2024.122774] [PMID]

17. Shi, Z., Yang, W.M., Chen, L.P., Yang, D.H., Zhou, Q., Zhu, J. et al., (2012). Enhanced chemosensitization in multidrug-resistant human breast cancer cells by inhibition of IL-6 and IL-8 production, Breast cancer research and treatment, 135, 737-747. http://doi.org/10.1007/s10549-012-2196-0 [DOI:10.1007/s10549-012-2196-0] [PMID]

18. Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal A., et al., (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA: a cancer journal for clinicians, 71(3), 209-249. http://doi.org/10.3322/caac.21660 [DOI:10.3322/caac.21660] [PMID]

19. Tao K., Fang M., Alroy J., and Sahagian, G.G. (2008). Imagable 4T1 model for the study of late stage breast cancer, BMC cancer, 8(1), 1-19. http://doi.org/10.1186/1471-2407-8-228 [DOI:10.1186/1471-2407-8-228] [PMID] [PMCID]

20. Wallace, K.B., Sardão, V.A. and Oliveira, P.J. (2020). Mitochondrial determinants of doxorubicin-induced cardiomyopathy, Circulation research, 126(7), 926-941. [DOI:10.1161/CIRCRESAHA.119.314681] [PMID] [PMCID]

21. Ye, Z., Hao, R., Cai, Y., Wang, X., Huang, G., (2016). Knockdown of miR-221 promotes the cisplatin-inducing apoptosis by targeting the BIM-Bax/Bak axis in breast cancer. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 37(4), 4509-15. http://doi.org/10.1016/j.biopha.2022.113903 [DOI:10.1016/j.biopha.2022.113903] [PMID]